Person profile

Public information reviewed

Jerome D. Jabbour

Role

Chairman, Chief Executive Officer and President at Matinas BioPharma Holdings, Inc. (NYSE: MTNB)

Board role

Director · Indaptus Therapeutics, Inc. (NASDAQ: INDP)

Board role

Chairman, Chief Executive Officer and President · Matinas BioPharma Holdings, Inc. (NYSE: MTNB)

Matinas BioPharma Holdings, Inc. (NYSE: MTNB)

Chairman, Chief Executive Officer and President · Current mandate

Director · Executive
FollowSave PDF
More
Reports & analysisAlpha Eval
Evidence records
7
Profile ownership
Not yet claimed
Record reviewed
Sep 6, 2026
View evidence

Profile

Identity, professional record and current appointments.

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
32 current organizations shown on this profile
Board positions
22 supported by public sources, 0 supplied by the profile owner
Committee roles
Not establishedNo committee role is currently confirmed by the cited sources
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

Co-founder of Matinas BioPharma appointed CEO in March 2018 and Chairman in March 2025. Previously served as Executive Vice President, Chief Business Officer, General Counsel and Secretary. Has extensive legal background including roles at MediMedia USA, Wockhardt Limited, and Reliant.

Sources are shown with the information they support.

Current roles

Appointments & responsibilities

Executive appointments

Board appointments

Governance

Board appointments, committee responsibilities and disclosed relationships.

Committee appointments across companies

Structured records are unavailable. This does not establish that no records exist.

Board and advisory record

Board service

Sources are shown with each role, education record, or credential.

Chairman, Chief Executive Officer and President

Matinas BioPharma Holdings, Inc.

Current · start date not disclosed

Confirmed by public sourceView source

Director

Indaptus Therapeutics, Inc.

Current · start date not disclosed

Confirmed by public sourceView source

Connections

Explore the roles, education and affiliations published in this record.

Indaptus Therapeutics, Inc.

Open Indaptus Therapeutics, Inc. profile →

Director at Indaptus Therapeutics, Inc.

Start not stated → End not stated

current · source reported

Observed: 2026-09-24

Indaptus Therapeut…Indaptus Therapeutics, Inc.Matinas BioPharma …Matinas BioPharma Holdings, Inc.Jerome D. Jabbour

Dashed lines mark past roles. Select a connection to see its dates and sources.

Relationship map

Connected through the public record

Direct relationships from verified facts and published résumé records. Private connections are excluded.

Direct public links only

Only published affiliations are shown here. Private relationships require authorized access.

Experience

Career history, education, credentials and public contributions.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · Sec FilingMTNB 10-K executive officersSupports AI and ML experience, Cybersecurity experience, Executive company, Executive title, Other Company Role, Technology background.Open sourceSource 2 · Sec FilingINDP 10-K executive officersSupports Executive company, Executive title.Open sourceSource 3 · Sec FilingINDP DEF 14A director slateSupports AI and ML experience, Board role, Committee assignments, Executive company, Executive title, Cybersecurity experience, Technology background.Open sourceSource 4 · Sec Def 14aPublic profile sourceSupports Chairman, Chief Executive Officer and President at Matinas BioPharma Holdings, Inc. (NYSE: MTNB).Open source

Basis

Identifiers, sources, dates and record limitations.

Identifiers

Alpha ID
alpha:person:jerome-d-jabbour
Record version
public-0

Published evidence records

7 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. MTNB 10-K executive officers

    sec filing · Source published: Mar 31, 2026 · Retrieved: May 16, 2026

    Supports 6 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Executive company: Executive at Matinas BioPharma Holdings, Inc. · Claim reviewed: May 16, 2026
    • Executive title: Executive title: Chairman, Chief Executive Officer, President and Interim Chief Financial Officer · Claim reviewed: May 16, 2026
    • Other Company Role: Jerome D. Jabbour is also linked to Indaptus Therapeutics, Inc. as Board Member. · Claim reviewed: May 16, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026

  2. INDP 10-K executive officers

    sec filing · Source published: Mar 17, 2026 · Retrieved: May 16, 2026

    Supports 2 claims
    • Executive company: Executive at Indaptus Therapeutics, Inc. · Claim reviewed: May 16, 2026
    • Executive title: Executive title: Director · Claim reviewed: May 16, 2026

  3. INDP DEF 14A director slate

    sec filing · Source published: Jan 21, 2026 · Retrieved: May 16, 2026

    Supports 7 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Board role: Board role: Director · Claim reviewed: May 16, 2026
    • Committee assignments: No committee assignment disclosed in the cited filing · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Executive company: Executive at Matinas BioPharma Holdings, Inc. · Claim reviewed: May 16, 2026
    • Executive title: Executive title: Chairman and Chief Executive Officer · Claim reviewed: May 16, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026

  4. Open source

    sec proxy · Source published: Jan 21, 2026 · Retrieved: Apr 25, 2026

    Supports 1 claim
    • Professional Role: Director at Indaptus Therapeutics, Inc. · Claim reviewed: Sep 6, 2026

  5. Open source

    sec def 14a · Source published: May 12, 2025 · Retrieved: Sep 6, 2026

    Supports 2 claims
    • Professional Role: Chairman, Chief Executive Officer and President at Matinas BioPharma Holdings, Inc. · Claim reviewed: Sep 6, 2026
    • Professional Role: Chairman, Chief Executive Officer and President at Matinas BioPharma Holdings, Inc. · Claim reviewed: Sep 6, 2026

  6. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Matinas BioPharma Holdings, Inc. · Claim reviewed: Sep 6, 2026

  7. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Indaptus Therapeutics, Inc. · Claim reviewed: Sep 6, 2026

Sources

Sources and published information

Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

AI and ML experience · CorroboratedAI and ML experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Board membership · Source reportedServes on the board of Indaptus Therapeutics, Inc.1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board membership · Source reportedServes on the board of Matinas BioPharma Holdings, Inc.1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board role · Source reportedBoard role: Director1 source
Verification
Source reported
Confidence
92%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Committee assignments · Source reportedNo committee assignment disclosed in the cited filing1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Cybersecurity experience · CorroboratedCybersecurity experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive company · Source reportedExecutive at Indaptus Therapeutics, Inc.1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive company · CorroboratedExecutive at Matinas BioPharma Holdings, Inc.Supported by 2 public records2 sources
Verification
Corroborated
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive title · Source reportedExecutive title: Chairman and Chief Executive Officer1 source
Verification
Source reported
Confidence
85%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive title · Source reportedExecutive title: Chairman, Chief Executive Officer, President and Interim Chief Financial Officer1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive title · Source reportedExecutive title: Director1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Other Company Role · Source reportedJerome D. Jabbour is also linked to Indaptus Therapeutics, Inc. as Board Member.1 source
Verification
Source reported
Confidence
70%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Technology background · CorroboratedTechnology background: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

View all sources7 records
  1. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: AI and ML experience · Cybersecurity experience · Executive company · Executive title · Other Company Role · Technology background

  2. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: Executive company · Executive title

  3. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: AI and ML experience · Board role · Committee assignments · Executive company · Executive title · Cybersecurity experience · Technology background

  4. https://www.sec.gov/Archives/edgar/data/1857044/000149315226003135/formdef14a.htm

    Sec Proxy · Tier not stated · Reviewed Apr 25, 2026

    Supports: Director at Indaptus Therapeutics, Inc. (NASDAQ: INDP)

  5. https://www.sec.gov/Archives/edgar/data/1582554/000164117225009754/formdef14-a.htm

    Sec Def 14a · Tier not stated · Reviewed Sep 6, 2026

    Supports: Chairman, Chief Executive Officer and President at Matinas BioPharma Holdings, Inc. (NYSE: MTNB)

  6. https://www.sec.gov/Archives/edgar/data/1582554/000164117225009754/formdef14-a.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership

  7. https://www.sec.gov/Archives/edgar/data/1857044/000149315226003135/formdef14a.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership